{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:41:09Z","timestamp":1760982069479},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11940-004-0010-y","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T19:34:15Z","timestamp":1180985655000},"page":"181-189","source":"Crossref","is-referenced-by-count":22,"title":["Psychosis in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"6","author":[{"given":"Laura","family":"Marsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1002\/mds.10567","volume":"18","author":"W Poewe","year":"2003","unstructured":"Poewe W: Psychosis in Parkinson\u2019s disease. Mov Disord 2003, 18:S80-S87. This is a detailed review of psychosis in PD, risk factors, and current treatment options.","journal-title":"Mov Disord"},{"key":"10_CR2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09540260020002541","volume":"12","author":"MJ Henderson","year":"2000","unstructured":"Henderson MJ, Mellers JDC: Psychosis in Parkinson\u2019s disease: \u201cbetween a rock and a hard place.\u201d Int Rev Psychiatry 2000, 12:319\u2013334. Henderson and Mellers provide another thorough review of psychosis in PD.","journal-title":"Int Rev Psychiatry"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G F\u00e9nelon","year":"2000","unstructured":"F\u00e9nelon G, Mahieux F, Huon R, Zi\u00e9gler M: Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology, and risk factors. Brain 2000, 123:733\u2013745. This is an interesting observational study on the range of hallucinatory phenomena in PD.","journal-title":"Brain"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","volume":"56","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Cummings JL, Laake K: Prevalence and clinical correlates of psychotic symptoms in Parkinson Disease: a community-based study. Arch Neurol 1999, 56:595\u2013601.","journal-title":"Arch Neurol"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1212\/WNL.51.3.811","volume":"51","author":"CG Goetz","year":"1998","unstructured":"Goetz CG, Vogel C, Tanner CM, Stebbins GT: Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998, 51:811\u2013814. This study showed that patients diagnosed with PD who have hallucinations early in the disease course often demonstrate evidence for alternative parkinsonian diagnoses over a 5-year follow-up period.","journal-title":"Neurology"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-510X(03)00220-X","volume":"216","author":"Y Horimoto","year":"2003","unstructured":"Horimoto Y, Matsumoto M, Nakazawa H, et al.: Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson\u2019s disease with dementia. J Neurol Sci 2003, 216:105\u2013108.","journal-title":"J Neurol Sci"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/mds.10274","volume":"17","author":"IH Richard","year":"2002","unstructured":"Richard IH, Papka M, Rubio A, Kurlan R: Parkinson\u2019s disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002, 17:1161\u20131165. Discusses the controversial issues related to distinguishing PD with dementia and dementia with Lewy bodies on clinical and neuropathologic grounds.","journal-title":"Mov Disord"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","volume":"64","author":"R Inzelberg","year":"1998","unstructured":"Inzelberg R, Kipervasser S, Korczyn AD: Auditory hallucinations in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1998, 64:533\u2013535.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10_CR9","unstructured":"Marsh L, Williams JR, Rocco M, et al.: Psychiatric comorbidities associated with psychosis in patients with Parkinson\u2019s disease [manuscript under review]."},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00415-002-0908-9","volume":"249","author":"G F\u00e9nelon","year":"2002","unstructured":"F\u00e9nelon G, Thobois S, Bonnet AM, et al.: Tactile hallucinations in Parkinson\u2019s disease. J Neurol 2002, 249:1699\u20131703.","journal-title":"J Neurol"},{"key":"10_CR11","first-page":"314","volume-title":"Parkinson\u015b Disease: Neurobehavioral Aspects","author":"JL Cummings","year":"1992","unstructured":"Cummings JL: Neuropsychiatric complications of drug treatment in Parkinson\u2019s disease. In Parkinson\u015b Disease: Neurobehavioral Aspects. Edited by Huber SJ, Cummings JL. New York: Oxford University Press; 1992:314\u2013327."},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","volume":"107","author":"N Giladi","year":"2000","unstructured":"Giladi N, Treves TA, Paleacu D, et al.: Risk factors for dementia, depression, and psychosis in long-standing Parkinson\u2019s disease. J Neural Transm 2000, 107:59\u201371. This is an interesting population-based study describing relationships between dementia and depression in the development of psychosis. Depressive disorders, especially in early onset PD, predicted the later onset of psychosis.","journal-title":"J Neural Transm"},{"key":"10_CR13","first-page":"41","volume":"3","author":"CE Peyser","year":"1998","unstructured":"Peyser CE, Naimark D, Zuniga R, Jeste DV: Psychoses in Parkinson\u2019s disease. Semin Clin Neuropsychiatry 1998, 3:41\u201350.","journal-title":"Semin Clin Neuropsychiatry"},{"key":"10_CR14","first-page":"419","volume-title":"Parkinson\u2019s Disease: Advances in Neurology","author":"CG Goetz","year":"1999","unstructured":"Goetz CG: Hallucinations in Parkinson\u2019s disease: the clinical syndrome. In Parkinson\u2019s Disease: Advances in Neurology, vol 80. Edited by Stern GM. Philadelphia: Lippincott Williams & Wilkins; 1999:419\u2013423."},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/PL00007822","volume":"248","author":"EC Wolters","year":"2001","unstructured":"Wolters EC: Intrinsic and extrinsic psychosis in Parkinson\u2019s disease. J Neurol 2001, 248(suppl):22\u201327. This is an interesting review that describes potential etiologies for PD-related psychosis.","journal-title":"J Neurol"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1212\/WNL.57.11.2078","volume":"57","author":"CG Goetz","year":"2001","unstructured":"Goetz CG, Leurgans S, Pappert EJ, et al.: Prospective longitudinal assessment of hallucinations in Parkinson\u2019s disease. Neurology 2001, 57:2078\u20132082.","journal-title":"Neurology"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.52.1.14","volume":"52","author":"E Melamed","year":"1999","unstructured":"Melamed E, Friedberg G, Zoldan J: Psychosis: impact on the patient and family. Neurology 1999, 52(suppl):S14-S16.","journal-title":"Neurology"},{"key":"10_CR18","first-page":"241","volume":"8","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH: Predictors of mortality among nursing home residents with a diagnosis of Parkinson\u2019s disease. Med Sci Monitor 2003, 8:241\u2013246.","journal-title":"Med Sci Monitor"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson\u2019s disease. Neurology 1993, 43:2227\u20132229.","journal-title":"Neurology"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","volume":"60","author":"S Factor","year":"2003","unstructured":"Factor S, Feustel PJ, Friedman J, et al.: Longitudinal outcome of Parkinson\u2019s disease patients with psychosis. Neurology 2003, 60:1756\u20131761.","journal-title":"Neurology"},{"key":"10_CR21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00002826-200307000-00001","volume":"26","author":"R Kurlan","year":"2003","unstructured":"Kurlan R: Declining medication requirements in some patients with Parkinson\u2019s disease. Clin Neuropharmacol 2003, 26:171.","journal-title":"Clin Neuropharmacol"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","volume":"8","author":"LM Shulman","year":"2002","unstructured":"Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Non-recognition of depression and other non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 2002, 8:193\u2013197.","journal-title":"Parkinsonism Relat Disord"},{"key":"10_CR23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"S Holroyd","year":"2001","unstructured":"Holroyd S, Currie L, Wooten GF: Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2001, 70:734\u2013738.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","volume":"14","author":"EJ Pappert","year":"1999","unstructured":"Pappert EJ, Goetz CG, Niederman FG, et al.: Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson\u2019s disease. Mov Disord 1999, 14:117\u2013121.","journal-title":"Mov Disord"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/01.nrl.0000038584.58012.de","volume":"9","author":"SG Reich","year":"2003","unstructured":"Reich SG, Marsh L: Ten questions: psychiatric aspects of Parkinson\u2019s disease. Neurologist 2003, 9:50\u201356.","journal-title":"Neurologist"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","volume":"72","author":"D Aarsland","year":"2002","unstructured":"Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson\u2019s disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002, 72:708\u2013712.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"I Leroi","year":"2004","unstructured":"Leroi I, Brandt J, Reich SG, et al.: Randomized placebo controlled trial of donepezil in cognitive impairment in Parkinson\u2019s disease. Int J Geriatr Psychiatry 2004, 19:1\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","volume":"16","author":"PJ Reading","year":"2001","unstructured":"Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001, 16:1171\u20131195.","journal-title":"Mov Disord"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Hutchinson M, Larsen JP: Cognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia. Int J Geriatr Psychiatry 2003, 18:937\u2013941.","journal-title":"Int J Geriatr Psychiatry"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1531-8257(199905)14:3<484::AID-MDS1016>3.0.CO;2-B","volume":"14","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH, Friedman JH, Jacques C, Rosenfeld M: Quetiapine for the treatment of drug induced psychosis in Parkinson\u2019s disease. Mov Disord 2003, 14:484\u2013487.","journal-title":"Mov Disord"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Parkinson Study Group","year":"1999","unstructured":"Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med 1999, 340:757\u2013763. This is a controlled trial using clozapine for treatment of psychosis in PD.","journal-title":"N Engl J Med"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","unstructured":"The French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson\u2019s disease. Lancet 1999, 353:2041.","journal-title":"Lancet"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1176\/appi.psy.42.6.477","volume":"42","author":"L Marsh","year":"2001","unstructured":"Marsh L, Lyketsos C, Reich SG: Olanzapine for the treatment of psychosis in patients with Parkinson\u2019s disease and dementia. Psychosomatics 2001, 42:477\u2013481.","journal-title":"Psychosomatics"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1353-8020(00)00024-9","volume":"7","author":"S Gim\u00e9nez-Rold\u00e0n","year":"2001","unstructured":"Gim\u00e9nez-Rold\u00e0n S, Mateo D, Navarro E, Gin\u00e9s MM: Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson\u2019s disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord 2001, 7:121\u2013127.","journal-title":"Parkinsonism Relat Disord"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","volume":"55","author":"CG Goetz","year":"2000","unstructured":"Goetz CG, Blasucci LM, Leurgans S, Pappert EJ: Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000, 55:789\u2013794.","journal-title":"Neurology"},{"key":"10_CR36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, et al.: Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry 2002, 52:438\u2013445.","journal-title":"Biol Psychiatry"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0735-6757(00)90023-8","volume":"18","author":"SA Factor","year":"2000","unstructured":"Factor SA, Molho ES: Emergency department presentations of patients with Parkinson\u2019s disease. Am J Emer Med 2000, 18:209\u2013215. Factor and Molho review clinical issues in the acute management of PD when there are catastrophic motor or neuropsychiatric disturbances.","journal-title":"Am J Emer Med"},{"key":"10_CR38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.52.4.777","volume":"52","author":"M Ueda","year":"1999","unstructured":"Ueda M, Hamamoto M, Nagayama H, et al.: Susceptibility to neuroleptic malignant syndrome in Parkinson\u2019s disease. Neurology 1999, 52:777\u2013781.","journal-title":"Neurology"},{"key":"10_CR39","first-page":"541","volume":"69","author":"J Zoldan","year":"1996","unstructured":"Zoldan J, Friedberg G, Weizman A, Melamed E: Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson\u2019s disease. Adv Neurol 1996, 69:541\u2013544.","journal-title":"Adv Neurol"},{"key":"10_CR40","first-page":"43","volume":"58","author":"RB Shulman","year":"2003","unstructured":"Shulman RB: Maintenance ECT in the treatment of PD. Geriatrics 2003, 58:43\u201345.","journal-title":"Geriatrics"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-004-0010-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-004-0010-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-004-0010-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:47Z","timestamp":1559437007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-004-0010-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11940-004-0010-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}